SCHEMBL4606969

SCHEMBL4606969

CCC(=O)Nc1ccc(COc2ccccc2)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DVL1 O14640 1/20 0.56
KDM4E B2RXH2 6/20 0.54
PKM P14618 2/20 0.54
ALDH1A1 P00352 7/20 0.51
LTC4S Q16873 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
HCAR2 Q8TDS4 1/20 0.48
HTT P42858 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CTSV O60911 2/20 0.47
CTSL P07711 2/20 0.47
HPGD P15428 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 2/20 0.47
MAPK10 P53779 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28966940 0.87 ALDH1A1 (0.60) DVL1KDM4EPKMALDH1A1MEN1
SCHEMBL4603523 0.85 MRGPRX4 (0.58) DVL1KDM4EPKMHTTMAPT
SCHEMBL4605146 0.84 DVL1 (0.52) DVL1KDM4EPKMCTSVCTSL
SCHEMBL1824454 0.84 MRGPRX4 (0.53) DVL1KDM4EPKMALDH1A1MEN1
SCHEMBL1824548 0.84 KDM4E (0.49) DVL1KDM4EPKMALDH1A1MEN1
SCHEMBL1824518 0.84 MAOB (0.49) DVL1KDM4EPKMALDH1A1MEN1
SCHEMBL4605129 0.83 DVL1 (0.51) DVL1KDM4EPKMALDH1A1MEN1
SCHEMBL4604528 0.82 KDM4E (0.70) DVL1KDM4EPKMALDH1A1LTC4S
SCHEMBL1825212 0.82 KDM4E (0.47) DVL1KDM4EPKMALDH1A1MEN1
SCHEMBL1826956 0.82 MAOB (0.52) DVL1KDM4EPKMALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 DVL1 4683/4885KDM4E 2898/4885PKM 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.